November 7, 2013 - Myeloma - Update on Treatment and Side Effects Management
- Goals of myeloma treatment
- Current and emerging therapies for myeloma, including updates on stem cell transplantation and maintenance therapy
- Updates on side effects management
- The importance of patient-provider communications in treatment and side effects management
Asher A. Chanan-Khan, MD
Professor of Medicine, Mayo School of Medicine
Chair, Division of Hematology/Oncology
Vice Chair, Research
Chair, Clinical Research Subcommittee
Assistant Director, Center for Individualized Medicine
Department of Medicine
Questions Asked by the Myeloma Community
- What are the benefits and risks of a chemotherapy holiday after 16 months of lenalidomide (Revlimid®) therapy, 12 months of bortezomib (Velcade®) plus Revlimid prior to the Revlimid alone?
- Could you speak about secondary cancers associated with taking Revlimid?
- What is the recommendation for the length of time a patient should be on Revlimid, after having melphalan previously?
- Can you compare the effectiveness of chemotherapy with a transplant? Does one approach lead to a better survival rate or is it patient-dependent?
- Would taking Revlimid and dexamethasone cause a side effect of short-term memory loss?
- Where can patients send their bodies for myeloma research when they die?
- What can be done to reduce skin reaction to the injection site when using Velcade?
- If immunoglobulins over-produce in myeloma, then why would a patient's immunoglobulins always be very low?
- How often should a PET or CT scan be done to track the lesions of multiple myeloma?